27061776|t|Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective
27061776|a|Adopting a unique Spanish perspective, this study aims to assess healthcare resource utilization (HCRU) and the costs of treating nosocomial pneumonia (NP) produced by methicillin-resistant Staphylococcus aureus (MRSA) in hospitalized adults using linezolid or vancomycin. An evaluation is also made of the renal failure rate and related economic outcomes between study groups. An economic post hoc evaluation of a randomized, double-blind, multicenter phase 4 study was carried out. Nosocomial pneumonia due to MRSA in hospitalized adults. The modified intent to treat (mITT) population comprised 224 linezolid - and 224 vancomycin - treated patients. Costs and HCRU were evaluated between patients administered either linezolid or vancomycin, and between patients who developed renal failure and those who did not. Analysis of HCRU outcomes and costs. Total costs were similar between the linezolid - (€17,782±€9,615) and vancomycin - treated patients (€17,423±€9,460) (P=.69). The renal failure rate was significantly lower in the linezolid - treated patients (4% vs. 15%; P<.001). The total costs tended to be higher in patients who developed renal failure (€19,626±€10,840 vs. €17,388±€9,369; P=.14). Among the patients who developed renal failure, HCRU (days on mechanical ventilation: 13.2±10.7 vs. 7.6±3.6 days; P=.21; ICU stay: 14.4±10.5 vs. 9.9±6.6 days; P=.30; hospital stay: 19.5±9.5 vs. 16.1±11.0 days; P=.26) and cost (€17,219±€8,792 vs. €20,263±€11,350; P=.51) tended to be lower in the linezolid - vs. vancomycin - treated patients. There were no statistically significant differences in costs per patient - day between cohorts after correcting for mortality (€1000 vs. €1,010; P=.98). From a Spanish perspective, there were no statistically significant differences in total costs between the linezolid and vancomycin pneumonia cohorts. The drug cost corresponding to linezolid was partially offset by fewer renal failure adverse events.
27061776	0	20	Nosocomial pneumonia	T047	C0949083
27061776	31	74	methicillin-resistant Staphylococcus aureus	T007	C1265292
27061776	75	87	treated with	T061	C0332293
27061776	88	97	linezolid	T109,T121	C0663241
27061776	101	111	vancomycin	T116,T195	C0042313
27061776	125	142	economic analysis	T057	C0680954
27061776	146	158	resource use	T078	C1704738
27061776	166	173	Spanish	T083	C0037747
27061776	174	185	perspective	UnknownType	C0680951
27061776	204	211	Spanish	T083	C0037747
27061776	212	223	perspective	UnknownType	C0680951
27061776	230	235	study	T062	C2603343
27061776	251	282	healthcare resource utilization	T078	C1704738
27061776	284	288	HCRU	T078	C1704738
27061776	298	303	costs	T081	C0085552
27061776	307	315	treating	T169	C1522326
27061776	316	336	nosocomial pneumonia	T047	C0949083
27061776	338	340	NP	T047	C0949083
27061776	354	397	methicillin-resistant Staphylococcus aureus	T007	C1265292
27061776	399	403	MRSA	T007	C1265292
27061776	408	427	hospitalized adults	T033	C0701159
27061776	434	443	linezolid	T109,T121	C0663241
27061776	447	457	vancomycin	T116,T195	C0042313
27061776	493	506	renal failure	T047	C0035078
27061776	507	511	rate	T081	C1521828
27061776	524	541	economic outcomes	T169	C1274040
27061776	550	562	study groups	UnknownType	C0681860
27061776	576	595	post hoc evaluation	T058	C1254363
27061776	601	611	randomized	T062	C2986910
27061776	613	625	double-blind	T062	C0013072
27061776	627	652	multicenter phase 4 study	T062	C0282462
27061776	670	690	Nosocomial pneumonia	T047	C0949083
27061776	698	702	MRSA	T007	C1265292
27061776	706	725	hospitalized adults	T033	C0701159
27061776	731	755	modified intent to treat	T169	C1292734
27061776	757	761	mITT	T169	C1292734
27061776	763	773	population	T098	C1257890
27061776	788	797	linezolid	T109,T121	C0663241
27061776	808	818	vancomycin	T116,T195	C0042313
27061776	821	828	treated	T061	C0332293
27061776	829	837	patients	T101	C0030705
27061776	839	844	Costs	T081	C0085552
27061776	849	853	HCRU	T078	C1704738
27061776	877	885	patients	T101	C0030705
27061776	886	898	administered	T169	C1521801
27061776	906	915	linezolid	T109,T121	C0663241
27061776	919	929	vancomycin	T116,T195	C0042313
27061776	943	951	patients	T101	C0030705
27061776	966	979	renal failure	T047	C0035078
27061776	1015	1019	HCRU	T078	C1704738
27061776	1020	1028	outcomes	T169	C1274040
27061776	1033	1038	costs	T081	C0085552
27061776	1046	1051	costs	T081	C0085552
27061776	1077	1086	linezolid	T109,T121	C0663241
27061776	1110	1120	vancomycin	T116,T195	C0042313
27061776	1123	1130	treated	T061	C0332293
27061776	1131	1139	patients	T101	C0030705
27061776	1170	1183	renal failure	T047	C0035078
27061776	1184	1188	rate	T081	C1521828
27061776	1220	1229	linezolid	T109,T121	C0663241
27061776	1232	1239	treated	T061	C0332293
27061776	1240	1248	patients	T101	C0030705
27061776	1281	1286	costs	T081	C0085552
27061776	1310	1318	patients	T101	C0030705
27061776	1333	1346	renal failure	T047	C0035078
27061776	1402	1410	patients	T101	C0030705
27061776	1425	1438	renal failure	T047	C0035078
27061776	1440	1444	HCRU	T078	C1704738
27061776	1446	1450	days	T079	C0439228
27061776	1454	1476	mechanical ventilation	T061	C0199470
27061776	1500	1504	days	T079	C0439228
27061776	1513	1521	ICU stay	T079	C1254367
27061776	1545	1549	days	T079	C0439228
27061776	1558	1571	hospital stay	T079	C3489408
27061776	1596	1600	days	T079	C0439228
27061776	1613	1617	cost	T081	C0085552
27061776	1688	1697	linezolid	T109,T121	C0663241
27061776	1704	1714	vancomycin	T116,T195	C0042313
27061776	1717	1724	treated	T061	C0332293
27061776	1725	1733	patients	T101	C0030705
27061776	1790	1795	costs	T081	C0085552
27061776	1800	1807	patient	T101	C0030705
27061776	1810	1813	day	T079	C0439228
27061776	1822	1829	cohorts	T098	C0599755
27061776	1851	1860	mortality	T081	C0392762
27061776	1895	1902	Spanish	T083	C0037747
27061776	1903	1914	perspective	UnknownType	C0680951
27061776	1977	1982	costs	T081	C0085552
27061776	1995	2004	linezolid	T109,T121	C0663241
27061776	2009	2019	vancomycin	T116,T195	C0042313
27061776	2020	2029	pneumonia	T047	C0032285
27061776	2030	2037	cohorts	T098	C0599755
27061776	2043	2052	drug cost	T081	C0085123
27061776	2070	2079	linezolid	T109,T121	C0663241
27061776	2094	2100	offset	T081	C1711330
27061776	2110	2123	renal failure	T047	C0035078
27061776	2124	2138	adverse events	T046	C0877248